ondansetron has been researched along with Cocaine-Related Disorders in 8 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Cocaine-Related Disorders: Disorders related or resulting from use of cocaine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cocaine abusers remain vulnerable to drug craving and relapse for many years after abstinence is achieved." | 3.74 | Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. ( Davidson, C; Ellinwood, EH; Lazarus, C; Lee, TH; Wetsel, WC; Zhang, X, 2007) |
| "Ondansetron is an indirect dopaminergic modulator that has shown efficacy in alcohol use disorder, particularly in phenotypic and genotypic subgroups, and was found to be efficacious in a pilot dose-finding trial for CUD." | 3.01 | A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis. ( Ait-Daoud, N; Blevins, D; Johnson, BA; Seneviratne, C; Wang, XQ, 2021) |
| "Ondansetron was well tolerated, causing no serious adverse events." | 2.72 | A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. ( Ait-Daoud, N; Bloch, DA; Elkashef, A; Harrison, JM; Javors, MA; Johnson, BA; Li, SH; Mojsiak, J; Roache, JD, 2006) |
| "Cocaine dependence is characterized by compulsive drug seeking and high vulnerability to relapse." | 2.47 | Promising medications for cocaine dependence treatment. ( Amore, M; Ciccocioppo, R; Donnini, C; Gerra, G; Gerra, ML; Kalluppi, M; Malagoli, M; Raggi, MA; Saracino, MA; Somaini, L, 2011) |
| "The ondansetron treated rats showed only a non-significant decrease in break point." | 1.31 | Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. ( Davidson, C; Ellinwood, EH; Lee, TH; Xiong, Z, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Blevins, D | 1 |
| Seneviratne, C | 1 |
| Wang, XQ | 1 |
| Johnson, BA | 2 |
| Ait-Daoud, N | 2 |
| Susukida, R | 1 |
| Crum, RM | 1 |
| Hong, H | 1 |
| Stuart, EA | 1 |
| Mojtabai, R | 1 |
| Somaini, L | 1 |
| Donnini, C | 1 |
| Raggi, MA | 1 |
| Amore, M | 1 |
| Ciccocioppo, R | 1 |
| Saracino, MA | 1 |
| Kalluppi, M | 1 |
| Malagoli, M | 1 |
| Gerra, ML | 1 |
| Gerra, G | 1 |
| Adinoff, B | 1 |
| Devous, MD | 1 |
| Williams, MJ | 1 |
| Harris, TS | 1 |
| Best, SE | 1 |
| Dong, H | 1 |
| Zielinski, T | 1 |
| Davidson, C | 3 |
| Lee, TH | 3 |
| Xiong, Z | 1 |
| Ellinwood, EH | 3 |
| Lazarus, C | 2 |
| Roache, JD | 1 |
| Javors, MA | 1 |
| Harrison, JM | 1 |
| Elkashef, A | 1 |
| Mojsiak, J | 1 |
| Li, SH | 1 |
| Bloch, DA | 1 |
| Zhang, X | 1 |
| Wetsel, WC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| New Medication Treatment for Stimulant Dependence[NCT00689572] | Phase 2 | 108 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants were assessed up to three times weekly for up to 9 weeks to evaluate cocaine use by self-report (NCT00689572)
Timeframe: up to 9 weeks
| Intervention | Percent of cocaine-free (abstinent)days (Mean) |
|---|---|
| Ondansetron | 67 |
| Placebo | 67 |
Urine samples were collected up to three times weekly for up to 9 weeks to test for the major cocaine metabolite benzoylecgonine (NCT00689572)
Timeframe: up to 9 weeks
| Intervention | Percent of cocaine-free urines (Mean) |
|---|---|
| Ondansetron | 16 |
| Placebo | 26 |
2 reviews available for ondansetron and Cocaine-Related Disorders
| Article | Year |
|---|---|
Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies.
Topics: Adult; Anti-Anxiety Agents; Buspirone; Central Nervous System Stimulants; Cocaine-Related Disorders; | 2018 |
Promising medications for cocaine dependence treatment.
Topics: Acetylcysteine; Atomoxetine Hydrochloride; Baclofen; Benzhydryl Compounds; Buprenorphine; Cocaine-Re | 2011 |
2 trials available for ondansetron and Cocaine-Related Disorders
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis.
Topics: Adult; Cocaine; Cocaine-Related Disorders; Double-Blind Method; Humans; Ondansetron; Pharmacogenomic | 2021 |
A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.
Topics: Adult; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Demograph | 2006 |
4 other studies available for ondansetron and Cocaine-Related Disorders
| Article | Year |
|---|---|
Differences in regional cerebral blood flow response to a 5HT3 antagonist in early- and late-onset cocaine-dependent subjects.
Topics: Adult; Age of Onset; Case-Control Studies; Cerebrovascular Circulation; Cocaine-Related Disorders; F | 2014 |
Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration.
Topics: Acute Disease; Animals; Behavior, Animal; Brain; Cocaine; Cocaine-Related Disorders; Disease Models, | 2002 |
Ondansetron, given during the acute cocaine withdrawal, attenuates oral cocaine self-administration.
Topics: Administration, Oral; Animals; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Male; Onda | 2004 |
Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors.
Topics: Animals; Behavior, Addictive; Brain; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dop | 2007 |